Clinical trials: Advanced Solid, Malignant Tumors
KRAS G12C Mutation Advanced Solid Tumor
Phase 1 Study of HS-10541 as Monotherapy or in Combination With Other Anti-cancer Therapies in Patients With KRAS G12C Mutation Advanced Solid Tumors.
This is a multicenter, open-label phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HS-10541 as monotherapy or in combination with other anti-cancer therapies in…
- Trial name
- NCT07615413
- Testing
- HS-10541
- Volunteers
- 636 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Advanced Cancer
A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors
The purpose of this study is to determine whether BMS-986249 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors
- Trial name
- NCT03369223
- Testing
- BMS-986249, Nivolumab, Ipilimumab
- Where
- 45 sites in United States, Argentina and 9 more
- Volunteers
- 356 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumors, Leukemia, Lymphocytic, Acute, Pediatric
Clofarabine in Adult Patients With Advanced Solid Tumors
Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment…
- Conditions
- Solid Tumors, Leukemia, Lymphocytic, Acute, Pediatric, Leukemia, Lymphocytic, Acute, Adult, Leukemia, Myelocytic, Acute, Pediatric
- Trial name
- NCT00125840
- Testing
- clofarabine (IV formulation)
- Where
- 2 sites in United States
- Sponsor
- Genzyme, a Sanofi Company
Pancreatic Cancer, Melanoma
Immunotherapy Study of Evofosfamide in Combination With Ipilimumab
An immunotherapy study combining ipilimumab and evofosfamide for the treatment of patients with confirmed metastatic or locally advanced prostate cancer, metastatic pancreatic cancer, melanoma or human papillomavirus (HPV)…
- Conditions
- Pancreatic Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Prostate Cancer
- Trial name
- NCT03098160
- Testing
- Evofosfamide, Ipilimumab
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Threshold Pharmaceuticals
ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
This study is designed to evaluate AZD8421 alone and in combination with selected targeted anti-cancer drugs in patients with ER+HER2- advanced breast cancer, and patients with metastatic high-grade serious ovarian cancer.
- Trial name
- CYCAD-1 (NCT06188520)
- Testing
- AZD8421, Camizestrant, Ribociclib
- Where
- 13 sites in United States, Australia and 3 more
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
HER2-positive Breast Cancer, HER2-positive Gastric Cancer
PRS-343 in HER2-Positive Solid Tumors
A multi center, open-label, Phase 1 dose escalation study with expansion cohort is designed to determine the MTD, RP2D and dosing schedule of PRS-343 in patients with HER2+ advanced or metastatic solid tumors.
- Conditions
- HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Bladder Cancer, HER2-positive Solid Tumor
- Trial name
- NCT03330561
- Testing
- PRS-343
- Where
- 10 sites in United States
- Volunteers
- 85 people
- Sponsor
- Pieris Pharmaceuticals, Inc.
Advanced Solid Tumors
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors
The primary objectives of this study are to characterize the safety and tolerability of evixapodlin (formerly GS-4224) and to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of evixapodlin in…
- Trial name
- NCT04049617
- Testing
- Evixapodlin
- Where
- 6 sites in United States, New Zealand
- Volunteers
- 18 people
- Sponsor
- Gilead Sciences
NSCLC Stage IV
HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC
This is a Phase 1, open-label, multicenter, dose escalation study of HY1272 (administered via IV) evaluating both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) in patients diagnosed with locally advanced or…
- Trial name
- NCT06218940
- Testing
- HY1272
- Volunteers
- 40 people
- Sponsor
- Newsoara Biopharma Co., Ltd.
Locally Advanced and Metastatic Solid Tumors
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
The primary objectives of this study were: to assess the safety and tolerability, to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and to determine the recommended Phase 2 dose (RP2D) of BGB-A1217…
- Trial name
- NCT04047862
- Testing
- Ociperlimab, Tislelizumab, Pemetrexed
- Where
- 65 sites in United States, Australia and 4 more
- Volunteers
- 446 people
- Sponsor
- BeiGene
Solid Tumor
Clinical Study of SPH3348 Tablets, a C-Met Inhibitor, in Patients with Advanced Solid Tumors
This is a phase 1 clinical trial of SPH3348 tablets, a c-Met inhibitor, in patients with advanced solid tumors with c-Met abnormalities.
- Trial name
- NCT05088070
- Testing
- SPH 3348
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Advanced Solid Tumor
A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors
This is a phase Ia clinical study evaluating H1710 for Injection in Participants with advanced solid tumors.
- Trial name
- NCT06992713
- Testing
- H1710 for Injection
- Where
- 4 sites in China
- Volunteers
- 36 people
- Sponsor
- Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Liver Cancer
Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose (MTD) and to investigate the efficacy, safety and pharmacokinetics of irofulven combined with oxaliplatin in patients with advanced solid tumors.
- Trial name
- NCT00374660
- Testing
- Oxaliplatin, Irofulven
- Where
- 7 sites in France
- Volunteers
- 63 people
- Sponsor
- Eisai Inc.
Advanced Solid Tumor, Metastatic Solid Tumor
A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors
This study will assess the safety and efficacy of JZP341 in participants with advanced or metastatic solid tumors.
- Trial name
- NCT05631327
- Testing
- JZP341
- Where
- 8 sites in United States
- Volunteers
- 12 people
- Sponsor
- Jazz Pharmaceuticals
Advanced Solid Tumors
A Study of BG-C477 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C477 alone and in combination with anticancer agents in participants with selected…
- Trial name
- NCT06596473
- Testing
- BG-C477, Tislelizumab, Chemotherapy
- Where
- 59 sites in United States, Australia and 6 more
- Volunteers
- 310 people
- Sponsor
- BeOne Medicines
Advanced Solid Tumors
Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors
This study is planned to be conducted in 2 parts: Part 1: Dose Escalation and Part 2: Safety Run-In and Randomized Expansion. The primary objectives of Part 1 are 1) To characterize the safety and tolerability of GS-3583 as…
- Trial name
- NCT04747470
- Testing
- GS-3583, Zimberelimab, Cisplatin
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Gilead Sciences
Cancer
CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma
RATIONALE: CT-322 may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer. PURPOSE: This phase I trial is studying the side effects of CT-322 in treating patients with advanced solid…
- Trial name
- NCT00374179
- Testing
- CT-322
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Adnexus, A Bristol-Myers Squibb R&D Company
Claudin 18.2, Solid Tumor Malignancies
A Phase I/II Study of FG-M108 Plus FG-B901 in Advanced CLDN18.2-Positive Solid Tumors
This open-label, multicenter Phase I/II trial evaluates the combination of FG-M108 and FG-B901 in patients with unresectable locally advanced or metastatic solid tumors that are positive for Claudin 18.2 and have progressed on…
- Trial name
- NCT07704866
- Testing
- FG-B901, FG-M108
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- FutureGen Biopharmaceutical (Beijing) Co., Ltd
Neoplasms, Breast Neoplasms
A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors
This is a Phase 1 study which consists of 2 parts; Dose Escalation part and Expansion part. The dose escalation part is open-label, and evaluates safety, preliminary efficacy and PK of single-agent talazoparib in sequential…
- Trial name
- NCT03343054
- Testing
- talazoparib
- Where
- 8 sites in Japan
- Volunteers
- 28 people
- Sponsor
- Pfizer
Locally Advanced, Recurrent or Metastatic Malignancies
SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors
This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Monotherapy and Combination Therapy in patients with advanced HER2-Expressing Solid Tumors.
- Trial name
- NCT07022002
- Testing
- SSGJ-705, PD-1/L1 inhibitor combined with chemotherapy, SSGJ-705 combined with chemotherapy
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Melanoma, Urothelial Carcinoma
A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Safety study of RC198 in Subjects with Solid Tumors.
- Conditions
- Melanoma, Urothelial Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT05867303
- Testing
- RC198 Injection
- Where
- 5 sites in Australia, China
- Volunteers
- 48 people
- Sponsor
- RemeGen Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.